NanoString and RikenGenesis Announce Partnership to CommercializenCounter-Based Diagnostic Assays in Japan
NanoString and Riken Genesis, a subsidiary of Sysmex, partner to register and commercialize
NanoString’s Lymphoma Subtyping Test for diagnostic use in Japan
SEATTLE and TOKYO, January 3, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc.
(NASDAQ:NSTG), a provider of life science tools for translational research and moleculardiagnostic products, and Riken Genesis, a subsidiary of Sysmex Corporation (TOKYO, 6869),
today announced that they have entered into a partnership to introduce nCounter-based
diagnostic assays in Japan.
Under this agreement, NanoString and Riken Genesis will collaborate to register, obtainreimbursement and commercialize companion diagnostic assays in Japan, including NanoString’s
Lymphoma Subtyping Test which will be marketed as the nCounter® Dx LymphMarkTM assay.
LymphMark is a 20-gene signature that classifies cell-of-origin subtypes of Diffuse Large B-cell
Lymphoma (DLBCL) tumors. The initial indication for the LymphMark assay is expected to be apotential companion diagnostic to aid in identifying DLBCL patients for treatment. TheLymphMark assay is based on the Lymph2Cx gene signature that was originally developed by theLymphoma/Leukemia Molecular Profiling Project (LLMPP) and has demonstrated analyticalrobustness and potential clinical utility.
The LymphMark assay was used to select patients in a Phase III clinical trial. The LymphMark
assay is being evaluated in more than 40 research studies that are being conducted with 23companies.
“Through this collaboration, we will work closely with Riken Genesis to launch novel diagnostic
products on the nCounter platform that may help guide decision making in the Japanese oncology
community,” said Brad Gray, chief executive officer of NanoString.
“We are pleased to partner with NanoString to bring new highly multiplexed molecular assays
to clinicians and patients in Japan,” said Dr. Naoto Kondo, president and chief executive officerof Riken Genesis. “These innovative assays will be an important addition to our portfolio of
diagnostic tests.”

About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and moleculardiagnostic products. The company's nCounter Analysis System has been employed in life sciences
research since it was first introduced in 2008 and has been cited in more than 1,800 peerreviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile
the expression of hundreds of genes, proteins, miRNAs, or copy number variations,
simultaneously with high sensitivity and precision, facilitating a wide variety of basic research andtranslational medicine applications, including biomarker discovery and validation. The company'stechnology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene
Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use asa prognostic indicator for distant recurrence of breast cancer. In addition, the company iscollaborating with multiple biopharmaceutical companies in the development of companion
diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
About Riken Genesis Co., Ltd.
RIKEN GENESIS, founded in October 2007, provides lab-assay services as well as products forgenetic testing based on cutting-edge gene analysis technologies and bioinformatics, and has
experience in the field of personalized medicine. The company provides highly reliable tests
based on international quality standards, as demonstrated by its CLIA certification, being the firstorganization in Japan to meet this U.S. quality control standard for clinical laboratories.
For more information, please visit https://rikengenesis.jp/
Forward-Looking Statements - NanoString
This news release contains forward-looking statements within the meaning of Section 27A of theSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995. These forward-looking statements include statements
regarding the outcomes of the research collaboration between NanoString and NSABP, including
the ability of the PanCancer IO 360 Gene Expression Panel and the Tissue Inflammation Signature
to identify novel biomarkers of the different mechanisms of immune evasion in colorectal tumors
and to identify tumors potentially responsive to PD-1 and PD-L1 blockade, and the use of theoutcomes of this research collaboration to guide the successful development of novelimmunotherapeutic approaches and combinations. Such statements are based on current
assumptions that involve risks and uncertainties that could cause actual outcomes and results todiffer materially. These risks and uncertainties, many of which are beyond our control, include
market acceptance of our products; delays or denials of regulatory approvals or clearances forproducts; the impact of competition; the impact of expanded sales, marketing, productdevelopment on operating expenses; delays or other unforeseen problems with respect tomanufacturing and product development; adverse conditions in the general domestic and global
economic markets; as well as the other risks set forth in the company's filings with the Securities
and Exchange Commission. These forward-looking statements speak only as of the date hereof.
NanoString Technologies disclaims any obligation to update these forward-looking statements.
For more information, please visit http://www.nanostring.com.
The NanoString logo, NanoString, NanoString Technologies, nCounter, PanCancer IO 360, andProsigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various
jurisdictions.
Contacts:Doug Farrell
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768

Jun Furukawa
General Manager, Sales & Marketing
Phone: +81-5759-6042
jun.furukawa@rikengenesis.jp